Press Releases

All Releases
Nektar Publishes Pre-clinical Results for NKTR-214, an Investigational CD122-Biased Immune-Stimulatory Cytokine for the Treatment of Cancer in Clinical Cancer Research
Feb 1, 2016
PDF 17.9 KB
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Jan 6, 2016
PDF 9.4 KB
Nektar Therapeutics to Present at Oppenheimer 26th Annual Healthcare Conference in New York
Dec 8, 2015
PDF 7.2 KB
Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine
Dec 8, 2015
PDF 14.4 KB
Baxalta Presents Additional Data on Newly-Approved ADYNOVATE and Plans for New Indications During 57th American Society of Hematology (ASH) Annual Meeting
Dec 7, 2015
PDF 92.2 KB
Baxalta Announces U.S. Availability of ADYNOVATE, A New Treatment for Adult Patients with Hemophilia A With a Simple, Twice-Weekly Dosing Schedule
Nov 30, 2015
PDF 64.8 KB
Nektar Therapeutics to Present at Jefferies Autumn 2015 Global Healthcare Conference in London
Nov 17, 2015
PDF 8.4 KB
Baxalta to Advance Care for Hemophilia A patients with FDA Approval of ADYNOVATE, a Simple, Twice-weekly Treatment to Reduce Bleeds
Nov 16, 2015
PDF 67.9 KB
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2015
Nov 5, 2015
PDF 28.8 KB
Nektar to Announce Financial Results for the Third Quarter 2015 on Thursday, November 5, 2015, After Close of U.S.-Based Financial Markets
Oct 29, 2015
PDF 10.0 KB
Nektar Reports on Advancements with Pain and Oncology Clinical Pipeline at Investor and Analyst R&D Day
Oct 8, 2015
PDF 13.5 KB
Nektar Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies
Oct 7, 2015
PDF 15.5 KB
Nektar Closes Direct Private Placement with TPG Special Situations Partners of $250 Million of Senior Secured Notes Due in 2020
Oct 6, 2015
PDF 13.2 KB
Nektar to Host Research & Development Day for Analysts and Investors on October 8th
Oct 1, 2015
PDF 13.0 KB
Nektar Presents Data Demonstrating that NKTR-214, a CD122-Biased Immunostimulatory Cytokine, Induces Durable and Specific Anti-Tumor Immunity As a Single-Agent and When Combined with Checkpoint Inhibitors in Preclinical Models
Sep 21, 2015
PDF 16.6 KB
Nektar Announces Receipt of $40 Million Milestone Payment Resulting from First Commercial Sale of MOVENTIG® (naloxegol) Tablets in Major European Market
Sep 1, 2015
PDF 12.7 KB
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2015
Aug 5, 2015
PDF 27.1 KB
Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets
Jul 29, 2015
PDF 10.0 KB
UPDATE: Baxalta's BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A
Jul 16, 2015
PDF 65.3 KB
Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine
Jun 2, 2015
PDF 16.8 KB
Showing 1-20 of 239 Page: 1 2 3 ... 12  Next 20
 
 
Site Map Privacy Terms of Use Trademarks Site Users Guide